Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Page 1
Acute phase determinant of post-thrombotic syndrome: A review of the literature.
Khider L, Planquette B, Smadja DM, Sanchez O, Rial C, Goudot G, Messas E, Mirault T, Gendron N. Khider L, et al. Among authors: sanchez o. Thromb Res. 2024 Apr 12;238:11-18. doi: 10.1016/j.thromres.2024.04.004. Online ahead of print. Thromb Res. 2024. PMID: 38643521 Free article. Review.
BACKGROUND: Post-thrombotic syndrome (PTS) is the main long-term complication of deep vein thrombosis (DVT). Several therapies are being evaluated to prevent or to treat PTS. ...
BACKGROUND: Post-thrombotic syndrome (PTS) is the main long-term complication of deep vein thrombosis (DVT). Several therapies are be …
Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.
Ghofrani HA, Simonneau G, D'Armini AM, Fedullo P, Howard LS, Jaïs X, Jenkins DP, Jing ZC, Madani MM, Martin N, Mayer E, Papadakis K, Richard D, Kim NH; MERIT study investigators. Ghofrani HA, et al. Lancet Respir Med. 2024 Apr;12(4):e21-e30. doi: 10.1016/S2213-2600(24)00027-4. Lancet Respir Med. 2024. PMID: 38548406 Clinical Trial.
BACKGROUND: Macitentan is beneficial for long-term treatment of pulmonary arterial hypertension. The microvasculopathy of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension are similar. ...
BACKGROUND: Macitentan is beneficial for long-term treatment of pulmonary arterial hypertension. The microvasculopathy of chronic thr …
Longitudinal Effects of Glucose-Lowering Medications on β-Cell Responses and Insulin Sensitivity in Type 2 Diabetes: The GRADE Randomized Clinical Trial.
Rasouli N, Younes N, Ghosh A, Albu J, Cohen RM, DeFronzo RA, Diaz E, Sayyed Kassem L, Luchsinger JA, McGill JB, Sivitz WI, Tamborlane WV, Utzschneider KM, Kahn SE; GRADE Research Group. Rasouli N, et al. Diabetes Care. 2024 Apr 1;47(4):580-588. doi: 10.2337/dc23-1070. Diabetes Care. 2024. PMID: 38211595 Clinical Trial.
OBJECTIVE: To compare the long-term effects of glucose-lowering medications (insulin glargine U-100, glimepiride, liraglutide, and sitagliptin) when added to metformin on insulin sensitivity and beta-cell function. ...After adjustment for HOMA2-%S to obtain an estimate of …
OBJECTIVE: To compare the long-term effects of glucose-lowering medications (insulin glargine U-100, glimepiride, liraglutide, and si …
Impact of Insulin Sensitivity and β-Cell Function Over Time on Glycemic Outcomes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE): Differential Treatment Effects of Dual Therapy.
Utzschneider KM, Younes N, Butera NM, Balasubramanyam A, Bergenstal RM, Barzilay J, DeSouza C, DeFronzo RA, Elasy T, Krakoff J, Kahn SE, Rasouli N, Valencia WM, Sivitz WI; GRADE Research Group. Utzschneider KM, et al. Diabetes Care. 2024 Apr 1;47(4):571-579. doi: 10.2337/dc23-1059. Diabetes Care. 2024. PMID: 38190619 Clinical Trial.
CONCLUSIONS: Insulin sensitivity and beta-cell function affected treatment outcomes irrespective of drug assignment, with greater impact in the sitagliptin group on initial (short-term) HbA1c response in comparison with the glimepiride and liraglutide groups....
CONCLUSIONS: Insulin sensitivity and beta-cell function affected treatment outcomes irrespective of drug assignment, with greater impact in …
Long-term neurological symptoms after acute COVID-19 illness requiring hospitalization in adult patients: insights from the ISARIC-COVID-19 follow-up study.
Battaglini D, White NM, Premraj L, Wanjiru Citarella B, Merson L, Robba C, Thomson D, Cho SM; ISARIC Clinical Characterization Group. Battaglini D, et al. J Neurol. 2024 Jan;271(1):79-86. doi: 10.1007/s00415-023-12133-y. Epub 2023 Dec 6. J Neurol. 2024. PMID: 38055020 Free PMC article. No abstract available.
Survivorship Care in Middle-Income Countries: A Guideline Development for Colombia Using Breast Cancer as a Model.
Peñaloza M, Sánchez O, García MA, Murillo R. Peñaloza M, et al. Among authors: sanchez o. JCO Glob Oncol. 2023 Sep;9:e2300018. doi: 10.1200/GO.23.00018. JCO Glob Oncol. 2023. PMID: 37769220 Free PMC article.
Cancer survival has significantly increased during the past few decades, making survivorship care a key element of cancer control and posing several challenges for long-term care in low- and middle-income countries (LMIC). Most survivorship care guidelines emphasize the po …
Cancer survival has significantly increased during the past few decades, making survivorship care a key element of cancer control and posing …
Mediterranean diet and psychological well-being intervention to reverse metabolic syndrome in Chile (CHILEMED trial).
Echeverría G, Samith B, von Schultzendorf A, Pinto V, Martínez X, Sara D, Calzada M, Pacheco J, Plaza G, Scott F, Romero J, Mateo C, Julio MV, Utreras-Mendoza Y, Binder MV, Gutiérrez F, Riquelme ME, Cuevas M, Willatt R, Sánchez O, Keilendt A, Butrón P, Jarufe A, Huete I, Tobar J, Martin S, Alfaro V, Olivos M, Pedrals N, Bitran M, Ávalos I, Ruini C, Ryff C, Pérez D, Berkowitz L, Rigotti A. Echeverría G, et al. Among authors: sanchez o. Contemp Clin Trials Commun. 2023 Jun 26;35:101167. doi: 10.1016/j.conctc.2023.101167. eCollection 2023 Oct. Contemp Clin Trials Commun. 2023. PMID: 37538196 Free PMC article.
We report here an ongoing randomized controlled clinical trial in Chilean patients with MetS seeking to test whether (1) a PWB theory-based intervention facilitates induction to and increases long-term adherence to a locally adapted MedDiet, and (2) a MedDiet intervention …
We report here an ongoing randomized controlled clinical trial in Chilean patients with MetS seeking to test whether (1) a PWB theory-based …
Long-term release of bioactive interferon-alpha from PLGA-chitosan microparticles: in vitro and in vivo studies.
Fleitas-Salazar N, Lamazares E, Pedroso-Santana S, Kappes T, Pérez-Alonso A, Hidalgo Á, Altamirano C, Sánchez O, Fernández K, Toledo JR. Fleitas-Salazar N, et al. Among authors: sanchez o. Biomater Adv. 2022 Dec;143:213167. doi: 10.1016/j.bioadv.2022.213167. Epub 2022 Oct 21. Biomater Adv. 2022. PMID: 36356469
In vitro and in vivo experiments demonstrated that the formulation improved the prophylactic and therapeutic potential of IFNalpha, accomplishing molecule protection and long-term release for at least two weeks. The procedure used to obtain IFNalpha-MPs is reproducible, sc …
In vitro and in vivo experiments demonstrated that the formulation improved the prophylactic and therapeutic potential of IFNalpha, accompli …
Pulmonary Embolism and Chronic Obstructive Pulmonary Disease.
Bertoletti L, Couturaud F, Sanchez O, Jimenez D. Bertoletti L, et al. Among authors: sanchez o. Semin Thromb Hemost. 2023 Nov;49(8):809-815. doi: 10.1055/s-0042-1756190. Epub 2022 Sep 15. Semin Thromb Hemost. 2023. PMID: 36108648 Review.
However, unlike other risk factors such as contraception, the presence of COPD can modify the initial presentation of VTE and worsen the short-term prognosis of patients who have acute pulmonary embolism (PE), particularly during a COPD exacerbation. ...
However, unlike other risk factors such as contraception, the presence of COPD can modify the initial presentation of VTE and worsen the sho …
58 results